反应详情

The title compound was prepared in analogy to Example 18, using enantiomerically pure 6-[(S)-1-(6-chloro-imidazo[1,2-b]pyridazin-3-yl)-ethyl]-5,7-difluoro-quinoline (Intermediate B, 50 mg, 0.145 mmol) and (R)-3-methyl-piperazin-2-one (33.1 mg, 0.29 mmol) instead of the racemates and flash chromatography for the purification. 2:1 mixture of title compound with compound of Example 60 (tR 3.59 min (conditions 5), tR 8.66 and 10.19 min (conditions 3, 90% n-hexane and 10% isopropanol), MH+=423.1, 1H-NMR in DMSO-d6: 8.91 (m, 1H); 8.42 (d, 1H); 7.90 (s, 1H); 7.80 (d, 1H); 7.69-7.50 (m, 3H); 7.05 (d, 1H); 4.93 (m, 1H); 4.50 and 4.28 (q, 1H); 3.87 (m, 1H); 3.43-2.89 (m, 3H); 1.84 (m, 3H); 1.30 and 0.93 (d, 3H)).

1. customfor the purification
2. addition2:1 mixture of title compound with compound of Example 60 (tR 3.59 min (conditions 5), tR 8.66 and 10.19 min (conditions 3, 90% n-hexane and 10% isopropanol), MH+=423.1, 1H-NMR in DMSO-d6: 8.91 (m, 1H); 8.42 (d, 1H); 7.90 (s, 1H); 7.80 (d, 1H); 7.69-7.50 (m, 3H); 7.05 (d, 1H); 4.93 (m, 1H); 4.50 and 4.28 (q, 1H); 3.87 (m, 1H); 3.43-2.89 (m, 3H); 1.84 (m, 3H); 1.30 and 0.93 (d, 3H))